Alterations in Cell Cycle Regulation Underlie Cisplatin Induced Apoptosis of Dorsal Root Ganglion Neurons in Vivo

Cisplatin is used in the treatment of ovarian and testicular cancer. Twenty percent of patients cannot be optimally treated because of sensory neurotoxicity. Human and animal studies demonstrate that the dorsal root ganglion neuron is the primary target of drug injury. We have previously demonstrated that cisplatin causes neuronal apoptosis in vitro. We now report a reproducible animal model of cell death induced by cisplatin. Drug was administered for 1 or 2 cycles of 5 days separated by 5 days. Total dose administered was 0, 5, 7.5, 10, or 15 mg/kg. Ganglia from 34 animals were processed and examined using in situ hybridization for cyclin D1 messenger RNA and digoxigenin coupled TUNEL staining. Overall, 2.9 +/- 3.9% of neurons were TUNEL positive in treated rats compared with 0.2 +/- 0.3% in controls (P <.005). There was a strong positive correlation (r2 = 0.88; P = 0.018) between percentage of TUNEL stained DRG and cumulative dose of cisplatin. Two independent approaches to quantitation of in situ cyclin D1 hybridization were used; blinded grading by an observer and measurement of color density using digital image analysis. Both demonstrated dramatic upregulation of expression of cyclin D1 mRNA in treated compared with control rats. This demonstrates that apoptosis of neurons is preceded by aberrant reentry into G1 phase of the cell cycle in an animal model.

[1]  M. Memo,et al.  Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path? , 2001, Trends in Neurosciences.

[2]  A. Windebank,et al.  Ceramide Initiates NFκB-Mediated Caspase Activation in Neuronal Apoptosis , 2000, Neurobiology of Disease.

[3]  David S. Park,et al.  Involvement of Retinoblastoma Family Members and E2F/DP Complexes in the Death of Neurons Evoked by DNA Damage , 2000, The Journal of Neuroscience.

[4]  J. Murguía,et al.  Sensing and responding to DNA damage. , 2000, Current opinion in genetics & development.

[5]  G. Cavaletti,et al.  Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. , 1999, Neurotoxicology.

[6]  R. Simon,et al.  Molecular Cloning of a Cell Cycle Regulation Gene Cyclin H from Ischemic Rat Brain , 1999, Journal of neurochemistry.

[7]  E. Raymond,et al.  Oxaliplatin: a review of preclinical and clinical studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  G. Cavaletti,et al.  Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. , 1998, Anticancer research.

[9]  A. Windebank,et al.  Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. , 1998, The Journal of clinical investigation.

[10]  G. Cavaletti,et al.  Carboplatin toxic effects on the peripheral nervous system of the rat. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  David S. Park,et al.  Inhibitors of Cyclin-dependent Kinases Promote Survival of Post-mitotic Neuronally Differentiated PC12 Cells and Sympathetic Neurons (*) , 1996, The Journal of Biological Chemistry.

[12]  J. Holst,et al.  Neuropeptides and Morphological Changes in Cisplatin-Induced Dorsal Root Ganglion Neuronopathy , 1996, Experimental Neurology.

[13]  L. Greene,et al.  Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  A. Levine,et al.  Cyclin D1 and p21/waf1 are both involved in p53 growth suppression. , 1996, Oncogene.

[15]  A. Zantema,et al.  Cyclin D1 is an essential mediator of apoptotic neuronal cell death. , 1996, The EMBO journal.

[16]  D. A. Thomas,et al.  Nerve growth factor alleviates a painful peripheral neuropathy in rats , 1995, Brain Research.

[17]  S. Lippard,et al.  Cisplatin and DNA repair in cancer chemotherapy. , 1995, Trends in biochemical sciences.

[18]  I. Barajon,et al.  An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. , 1995, Histology and histopathology.

[19]  G. Ferrari,et al.  N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  S. Estus,et al.  Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis , 1994, The Journal of cell biology.

[21]  G. Cavaletti,et al.  Protective effects of glutathione on cisplatin neurotoxicity in rats. , 1994, International journal of radiation oncology, biology, physics.

[22]  G. Cavaletti,et al.  Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. , 1994, In vivo.

[23]  S. Estus,et al.  Analysis of cell cycle-related gene expression in postmitotic neurons: Selective induction of cyclin D1 during programmed cell death , 1994, Neuron.

[24]  G. Pezzoni,et al.  Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. , 1993, Cancer research.

[25]  D. Stewart,et al.  Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Arezzo,et al.  Nerve growth factor prevents experimental cisplatin neuropathy , 1992, Annals of neurology.

[27]  E. Roubos,et al.  Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons. , 1990, Cancer research.

[28]  S. Wearden,et al.  Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy. , 1990, Gynecologic oncology.

[29]  A. Fojo,et al.  Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. , 1988, Cancer research.

[30]  R. Dubner,et al.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia , 1987, Pain.

[31]  Barnett Rosenberg,et al.  Charles F. Kettring prize. Fundamental studies with cisplatin , 1985 .

[32]  L. Davis,et al.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies , 1984, Cancer.

[33]  J. Rogin,et al.  Peripheral sensory neuropathy and cisplatin chemotherapy , 1984, Neurology.

[34]  T. J. Walsh,et al.  Neurotoxic effects of cisplatin therapy. , 1982, Archives of neurology.